Proactive Investors - Run By Investors For Investors

IXICO gets vote of confidence from big pharma

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes
Dollar bills
The value of the contract has been increased by 89%

IXICO PLC (LON:IXI), the data analytics company delivering insights in neuroscience, has seen the value of an existing contract almost double.

The company said the scope of a current contract with a top 10 biopharmaceutical company has been expanded, increasing the value of the contract by US$2.4mln over the remaining six-year term of the agreement to US$5.1mln.

READ IXICO trading ahead of expectations as digital tech permeates neuroscience sector

The announcement came on the same day as the publication of IXICO’s results for the year to the end of September, which showed continued strong revenue growth.

Revenue rose 32% to £5.39mln from £4.10mln the year before, while the gross margin improved to 58.8% from 56.4%.

The loss before tax narrowed to £793,000 from £1.91mln the previous year.

Operating cash outflows were reduced to around £100,000 from £1.2mln the previous year. Cash and cash equivalents at the end of the fiscal year had risen to £7.86mln from £2.41mln a year earlier.

CEO hails another year of significant progress

"2018 has been another year of significant progress in which we have delivered on our financial commitments, whilst continuing to invest in the long-term future of the company,” declared Giulio Cerroni, the chief executive officer of IXICO.

“We have reported record revenues with underlying growth of 41%, further improved gross profit performance and reduced operating losses. Consequently, operating cash outflows have been significantly reduced in the year to £0.1mln,” he noted.

“The combination of a strong order book and a healthy pipeline, in conjunction with senior management hires to execute our strategy, provides a solid foundation for continued growth momentum. With a successful capital placing to invest in new market and product development, we go into the new financial year with increased commercial traction, ambitious growth plans and a strengthened organisation focused on delivering technology-driven data analytics to our global biopharmaceutical clients," Cerroni concluded.

House broker sees acceleration along the path to profitability

House broker Shore Capital said the performance represented ongoing momentum from earlier reporting periods, with IXICO having now delivered more than 25% in reported revenue growth in the previous four reporting periods.

“Importantly, the revenue growth has been delivered from a strong performance across all of the business divisions, namely clinical trials services, Assessa PML, wearables projects and licensing revenue. We would also highlight IXICO’s performance in clinical trial services with £15m of new and expanded contracts secured in the period (including a further contract expansion announced separately today),” the broker said.

The contract wins in the reporting period also highlight the ongoing diversification of IXICO’s business as it moves away from a historical and predominant focus on Alzheimer’s disease to include several other neurological conditions, including Huntington’s disease and progressive supranuclear palsy, and the use of innovative technology for novel applications (wearable biosensors in psychiatric and neurological disorders), Shore observed.

“We remain excited by the revitalised focus on commercialisation and profitability and point to further evidence of accelerating momentum in this innovative digital health company,” the house broker concluded.

Shares in IXICO were up 4.3% at 24.5p at noon.

View full IXI profile View Profile

IXICO PLC Timeline

Newswire
December 11 2018

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use